There is no pill and never will be a pill that can address chronic metabolic disease because no medicine can reach where the problem actually is located

Fructose performs the Maillard (glycation) reaction seven times faster than glucose, accelerating protein browning and tissue damage

Antioxidants come from the food you eat, not from the air; sources include berries and leafy vegetables, but most people do not consume sufficient antioxidant-rich foods, leaving them vulnerable to oxidative damage

TOFI (thin on the outside, fat on the inside) individuals with equal trunk fat but different fat distribution—visceral/intra-abdominal fat versus subcutaneous fat—demonstrate dramatically different metabolic health outcomes; visceral fat is dangerous while subcutaneous fat is protective, making the location and type of body fat more predictive of health than total weight

Serum triglyceride is a measure of liver function because it represents very low density lipoproteins (VLDL) made by the liver from the conversion of sugar to fat through de novo lipogenesis; therefore, high triglycerides indicate the liver is sick from sugar consumption

Autophagy (cellular self-cleaning) declines with age and when impaired leads to cell death, cancer, immunosuppression, cardiomyopathy, neurodegenerative diseases, and infectious disease; increased autophagy is protective and improves health span

Type 2 diabetes incidence in children aged 10-14 and 15-19 has increased substantially over the past 20 years, and the fact that children are now developing adult-onset diseases indicates this is not a behavior or diet-exercise problem but rather an exposure problem—children are the canaries in the coal mine who are more sensitive to perturbations

U.S. healthcare expenditure and life expectancy diverged from all other OECD countries starting in 1980, with the U.S. falling off the rails while all 37 other developed countries remained relatively stable within their peer group

Life expectancy in the U.S. has been declining for the last five years in a row

Of the 42.4% of the U.S. adult population that is obese (BMI > 30), 80% are metabolically sick (sick because they're obese), but 20% are metabolically healthy obese (MHO) and will live a normal lifespan without costing taxpayers money; conversely, 60% of the normal-weight population (BMI < 30) have the exact same metabolic diseases as obese individuals, demonstrating that obesity is a risk factor but not a cause of metabolic disease

Non-alcoholic fatty liver disease (NAFLD), now called metabolically associated fatty liver disease (MAFLD), affects 45% of adults and 25% of children (regardless of obesity status), and is now the leading cause of liver transplant in the United States, having overtaken hepatitis C, despite the fact that children do not drink alcohol, pointing to a common environmental exposure affecting the entire population

Metabolic health and mental health are linked because both depend on mitochondrial function; mitochondria in the brain fail for the same reasons mitochondria in the liver fail, so the same metabolic interventions that fix metabolic syndrome also treat mental illness

LDL cholesterol correlates with cardiovascular disease at a hazard risk ratio of 1.3, but serum triglyceride correlates at 1.8, making serum triglyceride 50% more informative for predicting heart disease than LDL, yet the entire medical system focuses on lowering LDL

Statins fail to reduce cardiovascular mortality or events in primary prevention (treating high LDL in people without prior heart disease), and when they do show benefit in secondary prevention, the mean increase in lifespan is only four days, with a number needed to treat of 754 (meaning you must treat 754 people for one to benefit), far exceeding the threshold of cost-effectiveness

Statin use is associated with the development of diabetes because statins are mitochondrial toxins that inhibit 3-hydroxy-3-methylglutaryl-CoA reductase, a mitochondrial enzyme, causing mitochondrial damage

Five major randomized controlled trials show that lowering hemoglobin A1C (a primary diabetes treatment target) does not improve morbidity or mortality outcomes, including the UK PDS, ROSIE trial, and ACCORD trial, indicating that A1C reduction is not a valid surrogate for metabolic improvement

The eight subcellular pathologies driving chronic metabolic disease are: glycation, oxidative stress, mitochondrial dysfunction, insulin resistance, membrane instability, inflammation, methylation, and autophagy; none have medications that work (except possibly inflammation), but all are 'foodable'—fixable through dietary intervention

Glycation (non-enzymatic glycation of proteins) occurs through the Maillard reaction when glucose binds to the epsilon amino group of lysine, forming a Schiff base that spontaneously decomposes into an irreversible amidori rearrangement; this is the same browning process that occurs in food at high heat and occurs in the body at 98.6°F over 75 years

Ron Khan (researcher at Joslin Diabetes Center) concluded from his own research that high fructose in the diet is bad not because it has more calories but because it has specific metabolic effects that impair liver fat-burning capacity, causing the liver to store more fat, which is bad for the liver and whole-body metabolism

Glucose is 'good-ish' because it also raises insulin which has its own negative effects on chronic metabolic disease, making it metabolically neutral overall, while all other sugars are 'less bad' but still problematic